XyloCor Therapeutics Secures $67.5 Million for Gene Therapy
XyloCor Therapeutics, Inc., a pioneering biopharmaceutical company focused on developing innovative gene therapies for cardiovascular issues, recently announced the successful completion of a $67.5 million Series B financing. This crucial funding will propel the company’s clinical development efforts, particularly regarding its promising gene therapy, XC001, aimed at treating refractory angina.
Advancing Clinical Trials with New Funding
The newly acquired investment will primarily support a randomized, double-blind Phase 2b clinical trial named EXACT-2, targeting patients with refractory angina. The study will utilize a groundbreaking non-surgical technique for endocardial administration through a specialized injection catheter. Additionally, a second Phase 2 trial will investigate the potential of XC001 as an adjunctive therapy during coronary artery bypass graft surgery (CABG), serving a vital need for patients who lack effective treatment options.
Leading the Charge in Cardiovascular Gene Therapy
XyloCor's XC001 stands as a unique therapeutic option, addressing the needs of over one million individuals in the United States suffering from chronic cardiovascular conditions. The successful reception of this funding is led by Jeito Capital, a renowned private equity firm in life sciences investing. Jeito Capital’s involvement significantly enhances XyloCor’s capabilities and bolsters its Board of Directors with seasoned professionals, such as Rachel Mears, a Partner at Jeito.
Significant Milestones in Clinical Trials
The support from Jeito Capital signals confidence in XyloCor's progress and ambitions. CEO Al Gianchetti expressed his gratitude, emphasizing the importance of this investment in accelerating the clinical trials associated with XC001, paving the way for vital medical advancements for patients with cardiovascular diseases.
Innovative Approach to Cardiovascular Treatment
XyloCor is at the forefront of one-time gene therapy, targeting a demographic of patients with chronic heart conditions that have not responded to traditional treatments. The clinical potential of XC001 has been validated through promising outcomes from the Phase 1/2 trial, known as EXACT-1. The results indicate XC001's capacity to modify the disease, showcasing its effectiveness in alleviating chest pain and enhancing the quality of life for patients grappling with refractory angina.
Future Directions and Ongoing Studies
With evidence supporting efficacy and safety, XyloCor plans to launch the Phase 2b study in the upcoming years. XC001 intends to be administered using a streamlined catheter-based approach to deliver its therapeutic effects, offering a less invasive alternative compared to surgical options.
Transforming Outcomes with Gene Therapy
XyloCor's ambitions extend beyond refractory angina, as the company is also preparing to unveil a second Phase 2 trial for XC001 as a supplementary treatment to CABG, which is commonly performed to alleviate severe coronary artery disease. Approximately 400,000 CABG surgeries occur annually in the United States, yet many patients experience inadequate improvement due to issues like incomplete revascularization.
XC001’s Impact on Recovery and Health
By administering XC001 during CABG, the goal is to stimulate the growth of new blood vessels in regions of the heart not directly addressed by grafts, ultimately improving patient outcomes and reducing symptoms associated with coronary artery disease. As XyloCor gears up for the first patient dosing in late 2025, anticipation builds for the potential long-term benefits of this innovative therapy.
About XyloCor Therapeutics
XyloCor Therapeutics is dedicated to developing next-generation gene therapies aimed at radically advancing treatment options for patients affected by cardiovascular diseases. The company's flagship candidate, XC001, is currently positioned in clinical trials specifically for individuals with ischemic heart disease lacking existing therapies. XyloCor is also in the early stages of developing XC002 for cardiac tissue damage from heart attacks, holding exclusive licensing rights from Cornell University.
This ambitious approach reflects XyloCor's commitment to transforming the standard of care in cardiovascular medicine and improving patient lives significantly through advanced therapeutic innovations.
Frequently Asked Questions
What is XC001?
XC001 is a gene therapy developed by XyloCor Therapeutics aimed at treating patients with refractory angina and chronic cardiovascular diseases.
How much funding did XyloCor Therapeutics raise?
XyloCor Therapeutics secured $67.5 million in Series B financing to support its clinical developments.
What trials is XyloCor conducting for XC001?
XyloCor is conducting a Phase 2b trial named EXACT-2 and a trial investigating XC001 as an adjunct therapy to CABG.
What are the goals of XC001?
XC001 aims to promote the growth of new blood vessels in the heart, improving blood circulation and quality of life for patients with ischemic heart diseases.
When is the expected patient dosing for the Phase 2 study?
The first patient is expected to be dosed by late 2025 in the Phase 2b study of XC001.
